Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

NCT06495125 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Advanced Lung Adenocarcinoma
Refractory Lung Adenocarcinoma
Stage III Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8

Interventions

DRUG: Avutometinib
PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
DRUG: Defactinib
BIOLOGICAL: Nivolumab
PROCEDURE: Positron Emission Tomography

Sponsor

Emory University

Collaborators

[object Object]